Current proteomic analysis and post-translational modifications of biomarkers in human lung cancer materials
- PMID: 19097588
Current proteomic analysis and post-translational modifications of biomarkers in human lung cancer materials
Abstract
Lung cancer is the leading cause of cancer deaths worldwide and is often diagnosed in the advanced or late stages. The discovery of candidate biomarkers in human lung cancer materials holds clinical potential as well as a significant challenge. Due to a large number of proteins in human materials that form the protein complexity and post-translational modifications (PTMs) of proteins, proteomic analysis of lung cancer biomarkers remains a difficult task. Many proteomic approaches have been used to investigate the biomarkers in human lung cancer materials. In this review, we summarize the current proteomic approaches employed for analysis of proteome profiles in human lung cancer materials and some PTMs causing different proteome profiles and expression levels of biomarkers in lung cancer. In addition, bioinformatic tools for PTMs are useful for prediction of glycosylation and phosphorylation sites in proteins, which can help us further understand the correlation of PTMs and tumor development. However, it is necessary that proteome analysis of lung cancer materials be incorporated with new strategies and technologies to improve the efficiency of the analysis and to investigate novel biomarkers that would be very useful for further diagnostic and therapeutic applications.
Similar articles
-
Proteomics analysis in lung cancer: challenges and opportunities.Respirology. 2007 Jan;12(1):22-8. doi: 10.1111/j.1440-1843.2006.00957.x. Respirology. 2007. PMID: 17207021 Review.
-
Sub-speciating Campylobacter jejuni by proteomic analysis of its protein biomarkers and their post-translational modifications.J Proteome Res. 2006 Oct;5(10):2527-38. doi: 10.1021/pr050485w. J Proteome Res. 2006. PMID: 17022624
-
Proteomic approaches in lung cancer biomarker development.Expert Rev Proteomics. 2009 Feb;6(1):27-42. doi: 10.1586/14789450.6.1.27. Expert Rev Proteomics. 2009. PMID: 19210125 Review.
-
Enhanced detectability in proteome studies.J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 15;849(1-2):91-104. doi: 10.1016/j.jchromb.2006.10.065. Epub 2006 Nov 30. J Chromatogr B Analyt Technol Biomed Life Sci. 2007. PMID: 17140866 Review.
-
Biomarker discovery in lung cancer--promises and challenges of clinical proteomics.Mass Spectrom Rev. 2007 May-Jun;26(3):451-66. doi: 10.1002/mas.20125. Mass Spectrom Rev. 2007. PMID: 17407130 Review.
Cited by
-
Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its posttranslational modifications.Nucleic Acid Ther. 2013 Dec;23(6):435-42. doi: 10.1089/nat.2013.0439. Epub 2013 Oct 23. Nucleic Acid Ther. 2013. PMID: 24152208 Free PMC article.
-
Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer.Cancers (Basel). 2021 Sep 6;13(17):4489. doi: 10.3390/cancers13174489. Cancers (Basel). 2021. PMID: 34503301 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous